ACTIVE HALF-LIFE
5 days
CLASSIFICATION
Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER
Beligas - US
WAREHOUSE
USA Warehouse 2
SUBSTANCE
GIP/GLP-1 RA
Introducing Tirzepatide, a groundbreaking synthetic peptide designed to effectively lower glucose levels in the body. This innovative treatment enhances both the initial and secondary phases of insulin secretion while simultaneously reducing glucagon levels?actions that are intricately linked to the presence of glucose.
For individuals managing type 2 diabetes, Tirzepatide has shown remarkable benefits, including slowing gastric emptying, lowering both fasting and post-meal glucose levels, curbing appetite, and promoting weight loss. Additionally, it boosts insulin sensitivity, making it a powerful ally in diabetes management.
The unique structure of this peptide features a C20 fatty diacid component, which is linked via a hydrophilic connection to the lysine residue at position 20. This design ensures a strong binding affinity to albumin in the bloodstream, significantly extending its duration of action.
Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are present throughout the body, particularly in pancreatic beta-cells and the gastrointestinal tract. These receptors are pivotal in the progression of type II diabetes mellitus, as GLP-1R signaling is essential for glucose regulation. It promotes insulin release in response to glucose, slows gastric emptying, lowers blood glucagon levels, and activates brain pathways that suppress appetite. Alongside this, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 work together to maintain glucose balance by stimulating insulin secretion from pancreatic beta-cells, with GIP being the primary incretin hormone responsible for triggering insulin release upon food intake.
While the precise mechanisms of Tirzepatide are still being explored, its dual action on both GIP and GLP-1R is believed to be key to its effectiveness in controlling blood sugar and facilitating weight loss. Research suggests that combining GIP with a GLP-1R agonist yields an enhanced insulin response and reduced glucagon secretion compared to administering each hormone independently. Tirzepatide exhibits a high binding affinity for both GIP and GLP-1R, demonstrating a receptor binding affinity comparable to natural GIP, while its affinity for GLP-1R is five times lower than that of native GLP-1. By activating the GLP-1R signaling pathway, Tirzepatide stimulates insulin release in response to glucose through interactions with either the GIP receptor (GIPR) or the GLP-1R. However, further research is needed to fully understand the implications of GIPR activation in the drug's mechanism, as findings regarding its effects on blood glucose and weight management vary across both preclinical and clinical studies.